Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
National Lung Matrix Trial
2014-000814-73Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Jun 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of palbociclib, crizotinib, selumetinib, docetaxel and sitravatinib in non-small cell lung cancer (NSCLC) (5 cohorts), sponsored by University of Birmingham. Primary endpoint: Signal of activity / adequate tumour response. Status: unknown.
02
Drugs
palbociclibcrizotinibselumetinibdocetaxelsitravatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-000814-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000814-73.